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Abstract Background:Many review articles report the safety and lackof serious side-effects associatedwith the his-
tamine challenge.Eventhoughmethacholine andhypertonic saline aremore commonlyusedtomeasure airwayrespon-
siveness, histaminechallenges areusedinmanycountriesaroundtheworld.Levelsof subjectsdiscomfort after achallenge
havenotbeenquantified.This studyquantified the incidence, severityandduration of subjectdiscomfort afterhistamine
challenge. Methods: Ninety-nine subjects were recruited in an Australian multi-centre population-based study of the
genetic epidemiologyof asthma.Subjects completed a histamine challengewith final cumulative dose 3.2 mmol. Immedi-
ately, and10min, after challenge subjects rated their discomfort for cough, headache, throat irritation, hoarse voice and
flushed.Researchpersonnel alsoreportedtheirperceptionof subjectdiscomfort.Results:Subjects andresearchperson-
nel reported a small degree of subject discomfort for all symptoms immediately after the histamine challenge.Overall,
median symptomscoreswere less than1.5 outof10.Discomfort scoresimproved10min afterchallenge andcough, throat
irritation and flushed improved significantly.Conclusions:This study confirms the tolerability of the histamine challenge.
r 2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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The histamine challenge is used to measure airway re-
sponsiveness and has been used widely in both research
and clinical settings over many decades. Although other
challenge agents, which produce fewer side-e¡ects, are
now more commonly used in epidemiological studies,
there are still a signi¢cant number of research projects,
conducted in a variety of countries, which continue to
measure airway responsiveness using histamine. A num-
ber of review articles have described challenge tests as
safe and lacking in serious side-e¡ects (1^3). Although
the histamine challenge is widely accepted in the ¢eld of
respiratory medicine and the test is well tolerated by
subjects, there are no published quantitative data about
the incidence, severity and duration of subject discom-
fort associatedwith undergoing a histamine challenge.
Increasingly,HumanEthicsCommittees and consumer
groups are placing pressure on clinicians and researchers
to provide evidence for statements such as ‘‘minimal dis-
comfort’’ and ‘‘limited side-e¡ects’’ which commonly ap-Received14 August 2001, accepted in revised form 29 April 2002
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These advocates argue subjects should not be asked to
provide informed consent to undergo clinical investiga-
tions unless the subject is made aware of the type, dura-
tion and likelihood of discomfort and inconvenience (4).
In this study, we report the level of subject discomfort
associated with the histamine challenge, using speci¢c
and open-ended questions. In addition, the research per-
sonnel who performed the histamine challenge indepen-
dently rated their perception of the subject’s level of
discomfort for comparison.The datawere obtained dur-
ing an epidemiological study in Australian adults.
METHODS
The subjects enrolled in this study were participants in
an Australian multi-centre population-based study of
the genetic epidemiology of asthma and atopy. Across
the three centres,99 consecutive adult subjects who un-
derwent the histamine challenge as part of the standard
study protocol were enrolled. The Human Ethics Com-
mittees at each of the testing centres approved the pro-
tocol and all subjects gavewritten consent to be involved
in this study.
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During the challenge, histamine was administered by
DeVilbiss No. 45 plastic hand-held nebulisers using the
rapidmethod (5).Doses of 0.06, 0.24 and 0.49 mmolwere
administered inup to seven steps to provide a ¢nal cumu-
lative dose of 3.92mmol. All doseswere administeredun-
til either the ¢nal dose hadbeen reached or the subject’s
FEV1had declined by at least 20%. Spirometry was mea-
sured according to the1995 ATS standard (6).
At the completion of the challenge and after answer-
ing the symptom scale questionnaire, subjectswho had a
decrease in FEV1 of more than 10% from baseline were
given 200mg salbutamol via spacer to aid recovery.
Symptomscale questionnaire
Immediately after the conclusion of the histamine chal-
lenge, each subject was asked to complete a symptom
scale questionnaire that consisted of a 10 cm line drawn
under each of the following six symptoms: cough, head-
ache, throat irritation, hoarse voice, £ushed and other
(describe). The line was anchored at the left with the
word ‘‘none’’ and at the right with the phrase ‘‘the worst
I can imagine’’ (7). For each of the symptoms, written in-
structions asked the subject to rate their level of discom-
fort on this visual analogue scale, at that moment, by
marking the line at the appropriate place or to tick a
boxmarked ‘‘none’’. An identical questionnairewas com-
pleted10min later.
Themark on the10 cm visual analogue scale wasmea-
sured with a ruler to the nearest millimetre.The scores
ranged fromapossible 0.0 through to10.0,with the check
box ‘‘none’’ coded as a 0.0 score. The ‘‘none’’ check box
was included to avoid researcher misinterpretation ofTABLE1. Comparison of discomfort levels after histamine challe
Comparison of subject level of discomfort
0min after
histamine
challenge
10min after
histamine
challenge
P v
Median score (IQR) Median score (IQR)
Cough 1.0 (2.5) 0.5 (1.7) 0.
Headache 0.0 (0.5) 0.0 (0.0) 0.
Throat irritation 1.3 (3.0) 0.5 (2.0) 0.
Hoarse voice 1.3 (3.2) 0.5 (2.5) 0.
Flushed 0.0 (1.3) 0.0 (0.4) 0.0
Note:Discomfort scoreFMin: 0 max:10.very minimal discomfort marked on the visual analogue
scale being scored as 0.0.
The research personnelwho performed the challenge
wereprovidedwith an identical symptom scale question-
naire.Theyrated their perception of the subject’s level of
discomfort immediately after completion of the hista-
mine challenge without seeing the patient’s question-
naire responses.
Statistical analyses
Statistical analyses were performed with the statistical
program SAS (version 6.22, Cary, NC: SAS Institute
Inc). Data were compared using medians and interquar-
tile ranges (IQR) because all variableswerenon-normally
distributed. Comparisons between subject discomfort
scores at 0 and10min andbetween subject andresearch-
er scores at 0minwere performedusing Friedman’s ana-
lysis of variance.Comparisonsbetween theprevalence of
symptoms at 0 and10min were performed usingMcNe-
mar’s test.
RESULTS
The left-hand side of theTable1shows the comparison of
subject discomfort for each of the symptoms measured
immediately after the histamine challenge and10min la-
ter.The right-hand side of Table 1 shows the comparison
of subject discomfort and the researchers’ perception of
subject discomfort for each of the symptoms immedi-
ately after the histamine challenge. Both the subjects
and research personnel reported a small degree of sub-
ject discomfort for each of the symptoms after comple-
tion of the histamine challenge. Overall, no median
symptom scorewas greater than1.5 out of a possible10.nge
Comparison of subject level of discomfort
vs.
researcher perception of subject level of discomfort
alue Subject 0min
afterhistamine
challenge
Researcher
perception 0min
afterhistamine
challenge
P value
Median score (IQR) Median score (IQR)
018 1.0 (2.5) 0.5 (1.8) 0.035
152 0.0 (0.5) 0.0 (0.0) 0.002
011 1.3 (3.0) 0.0 (1.5) o0.001
202 1.3 (3.2) 0.0 (1.5) 0.002
04 0.0 (1.3) 0.0 (1.0) 0.014
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ately after histamine challenge and 10min later showed
that the level of discomfort had statistically signi¢cantly
improved for cough, throat irritation and feeling £ushed.
There was no statistically signi¢cant di¡erence for the
symptoms of headache and hoarse voice although both
median symptom scores moved in the direction of im-
provement. Subjects added 12 extra symptoms in the
‘‘Other (describe)’’ section. Eight subjects added chest
tightness, four added light-headed, three added wheezy,
dizzy or uneasybreathing and two added itchyunder the
jaw. Individual subjects reported each of the six remain-
ing symptoms.
The proportion of subjects who reported each of the
symptoms immediately after the challenge was: cough
67%, headache 27%, throat irritation 73%, hoarse voice
67% and £ushed 44% and10min after the challengewas:
cough100%, headache19%, throat irritation 59%, hoarse
voice 61% and £ushed 27%.Cough increased signi¢cantly
(Po0.001) and headache (Po0.01), throat irritation
(Po0.01) and £ushed (Po0.01) decreased signi¢cantly
10min after histamine challenge.
Research personnel recorded lower subject discom-
fort scores than did the subjects immediately after the
challenge. Comparison of subject level of discomfort
with research personnel perception of subject discom-
fort immediately after the histamine challenge statisti-
cally signi¢cantly underestimated the level of subject
discomfort for all symptoms.
DISCUSSION
This study provides evidence that statements such as
‘‘minimal discomfort’’ and ‘‘limited side-e¡ects’’, which
commonly appear on subject information sheets and
consent forms for the histamine challenge, are entirely
appropriate. Additionally, while the level of subject dis-
comfort was minimal, research personnel were likely to
underestimate the actual level of discomfort experi-
enced by subjects.
The study was limited by the fact that the symptom
questionnairewas also not administeredprior to thehis-
tamine challenge. However, such baseline assessment
would have reduced rather than increased the e¡ect at-
tributable to histamine challenge. Also, we have not at-
tempted to relate level of discomfort to the dose of
histamine administered. Most subjects (n=77) received
the ¢nal cumulative dose of 3.92mmol of histamine and
we feel that this fact combined with the very low dis-
comfort scores makes further subgroup analyses unne-
cessary.Participants in research studies and patients under-
going clinical tests have a right to be informed of the ex-
pected level of discomfort associated with clinical
investigations. As such, anecdotal reports andclinical ex-
perience are not su⁄cient evidence for subjectswho are
being asked for informed consent or to convince ethics
committees of the value of including particular investiga-
tions in research protocols.
We are not aware of any other studies in which mea-
sures of discomfort associated with the histamine chal-
lenge have been quanti¢ed.Our epidemiology team has
conducted well in excess of 10 000 challenges over the
last 18 years and all have been performed without ser-
ious adverse events. However, in multi-centre projects
it has been troublesome to convince respective Human
Ethics Committees who have not had experience with
these clinical tests of their safety, tolerability and low le-
vel of discomfort. The current study provides objective
evidence of the tolerability of histamine challenge in a
general population sample. This information will assist
researchers and Human Ethics Committees who are un-
familiar with challenge testing in the performance of
their role of balancing subject discomfort and inconveni-
encewith the level of gain from conducting the research.
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